Alibhai Shabbir M H, Leach Marc, Gupta Vikas, Tomlinson George A, Brandwein Joseph M, Saiz Fernando Suarez, Minden Mark D
Division of General Internal Medicine & Clinical Epidemiology, University Health Network, Toronto, Canada.
Crit Rev Oncol Hematol. 2009 Feb;69(2):168-74. doi: 10.1016/j.critrevonc.2008.07.015. Epub 2008 Sep 7.
Although intensive chemotherapy may improve survival in older people with acute myeloid leukemia (AML) without adverse cytogenetics, its impact on quality of life (QOL) is mixed and most patients complain of fatigue up to 6 months after diagnosis. Little information is available on longer-term QOL outcomes. We prospectively followed 20 patients age 60 or older with AML who provided QOL data more than 6 months after diagnosis. Over the first 6 months, there were clinically important improvements in global health, role function, social function, and emotional function. Physical function and cognitive function were stable over time. Over the next 6 months, social function and fatigue improved, and other domains remained stable. Achievement of complete remission appeared to be associated with improvements in global health, physical function, and role function without negatively affecting other health domains. This information may aid discussions with patients about treatment.
尽管强化化疗可能会提高无不良细胞遗传学特征的老年急性髓系白血病（AML）患者的生存率，但其对生活质量（QOL）的影响好坏参半，大多数患者在诊断后长达6个月都抱怨疲劳。关于长期生活质量结果的信息很少。我们前瞻性地跟踪了20名60岁及以上的AML患者，他们在诊断后6个月以上提供了生活质量数据。在最初的6个月里，全球健康、角色功能、社会功能和情感功能有临床上重要的改善。身体功能和认知功能随时间保持稳定。在接下来的6个月里，社会功能和疲劳有所改善，其他领域保持稳定。完全缓解的实现似乎与全球健康、身体功能和角色功能的改善有关，而不会对其他健康领域产生负面影响。这些信息可能有助于与患者讨论治疗方案。
